

Original Article

Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors

Tong-chao LIU^{1,2}, Xia PENG³, Yu-chi MA², Yin-chun JI³, Dan-qi CHEN², Ming-yue ZHENG², Dong-mei ZHAO^{1,*}, Mao-sheng CHENG¹, Mei-yu GENG³, Jing-kang SHEN², Jing AI^{3,*}, Bing XIONG^{2,*}

¹Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; ²Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; ³Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Aim: Aberrant c-Met activation plays a critical role in cancer formation, progression and dissemination, as well as in development of resistance to anticancer drugs. Therefore, c-Met has emerged as an attractive target for cancer therapy. The aim of this study was to develop new c-Met inhibitors and elaborate the structure-activity relationships of identified inhibitors.

Methods: Based on the predicted binding modes of Compounds **5** and **14** in docking studies, a new series of c-Met inhibitor-harboring 3-((1*H*-pyrrolo[3,2-*c*]pyridin-1-yl)sulfonyl)imidazo[1,2-*a*]pyridine scaffolds was discovered. Potent inhibitors were identified through extensive optimizations combined with enzymatic and cellular assays. A promising compound was further investigated in regard to its selectivity, its effects on c-Met signaling, cell proliferation and cell scattering *in vitro*.

Results: The most potent Compound **31** inhibited c-Met kinase activity with an IC₅₀ value of 12.8 nmol/L, which was >78-fold higher than those of a panel of 16 different tyrosine kinases. Compound **31** (8, 40, 200 nmol/L) dose-dependently inhibited the phosphorylation of c-Met and its key downstream Akt and ERK signaling cascades in c-Met aberrant human EBC-1 cancer cells. In 12 human cancer cell lines harboring different background levels of c-Met expression/activation, Compound **31** potently inhibited c-Met-driven cell proliferation. Furthermore, Compound **31** dose-dependently impaired c-Met-mediated cell scattering of MDCK cells.

Conclusion: This series of c-Met inhibitors is a promising lead for development of novel anticancer drugs.

Keywords: c-Met inhibitors; hepatocyte growth factor receptor; imidazo[1,2-*a*]pyridine; anticancer agents; drug discovery

Acta Pharmacologica Sinica (2016) 37: 698–707; doi: 10.1038/aps.2016.11; published online 4 Apr 2016

Introduction

c-Met, also known as hepatocyte growth factor receptor (HGFR), was discovered in 1984 as an oncogenic fusion protein^[1]. Since then, extensive investigations on the structure and functions of c-Met have shown that it belongs to a unique subfamily of receptor tyrosine kinases (RTKs)^[2] and forms a heterodimer by connecting a short extracellular α chain and a membrane spanning β chain through a disulfide bond. After binding to its natural ligand, hepatocyte growth factor (HGF), c-Met initiates its kinase phosphorylation activity and triggers a series of downstream signaling pathways, including PI3K-AKT-mTOR and Ras-MEK-ERK^[3–7]. Abnormal activation of

c-Met has been linked to many types of cancers that occur as a consequence of gene amplification or rearrangement, transcriptional regulation, as well as autocrine or paracrine ligand stimulation^[8]. Importantly, both c-Met and HGF elevation have been associated with poor clinical outcomes^[9]. Moreover, aberrant c-Met activation plays a critical role in cancer formation, progression, and dissemination and in the development of resistance against approved therapies. Therefore, c-Met has emerged as an attractive target for cancer therapy^[10–16].

Currently, the most promising approach for disrupting c-Met signaling is to use small molecular inhibitors to target the intracellular kinase domain. Through the analysis of binding modes, small molecule inhibitors of c-Met can be roughly classified into three types. Type I c-Met inhibitors bind to ATP binding pockets in a “U” shape, which usually interacts with residue Met1211 at the hinge part to anchor the inhibitor and forms a typical π - π stacking interaction with residue

* To whom correspondence should be addressed.

E-mail bxiong@simm.ac.cn (Bing XIONG);

jai@simm.ac.cn (Jing AI)

Received 2015-11-10 Accepted 2016-01-05




Figure 1. Representative c-Met inhibitors.


Tyr1230^[17]. As implied by the unique U-shaped binding mode, type I inhibitors (such as crizotinib **1**) all show good selectivity for c-Met and are expected to cause fewer side effects in cancer treatment^[18]. Type II c-Met inhibitors (such as cabozantinib **2**) are usually multi-kinase inhibitors and adopt extended conformations, starting from the solvent-accessible part to hinge and further stretching to the deep hydrophobic Ile1145 subpocket near the C-helix region^[19]. Except for the above-mentioned well-classified inhibitors, there are other atypical c-Met inhibitors, such as ARQ197 (**3**), that are all classified as type III c-Met inhibitors^[20].

Previously, we elaborated on the synthesis of a series of pyrazolo[4,3-b]pyridine compounds and their potent and selective activities as c-Met inhibitors (lead compound **4**)^[21]. During the optimization process, we synthesized an interesting compound (**5**) containing two possible hinge binders, an imidazole ring and an imidazo[1,2-a]pyridine ring, which could form an essential hydrogen bonding interaction with the backbone of Met1160. Considering its interesting binding mode and good enzymatic activity, we initialized a medicinal chemistry modification with the aim of finding a novel series of c-Met inhibitors for the further development of anti-cancer drugs.

Materials and methods

Chemistry


Scheme 1



Reagents and conditions: (a) ClSO_3H , CHCl_3 , Reflux, 24 h, 98%; (b) (4-fluorophenyl)boronic acid, $\text{Pd}(\text{dppf})\text{Cl}_2$, K_2CO_3 , 90 °C, 3 h, 70.9%; (c) phosphorus oxychloride, reflux, 24 h, 51%; (d) NaH, DMF, room temperature, 4 h.

Compounds **5–19** were prepared according to the procedure shown in Scheme 1. Commercially available **32** was sulfonylated to afford **33**. Conventional Suzuki coupling of **33** with (4-fluorophenyl)boronic acid afforded compound **34**. Treatment of compound **34** with phosphorus oxychloride afforded compound **35**. Compounds **5–19** were prepared by subjecting compound **35** to condensation with the appropriate pyrazole derivatives.

Scheme 2



Reagents and conditions: (a) phosphorus oxychloride, reflux, 24 h, 51%; (b) 1H-pyrrolo[3,2-c]pyridine, NaH, DMF, room temperature, 4 h, 60%; (c) R-boronic acid or R-boronic acid pinacol ester, $\text{PdCl}_2(\text{dppf})\text{-CH}_2\text{Cl}_2$, K_2CO_3 , 90 °C, 30 min, 31%–81%.

Compounds **20–31** were synthesized according to the procedures outlined in Scheme 2. Compound **33** was treated with phosphorus oxychloride to afford compound **36**. Compound **37** was prepared by deprotonating 5-azaindole, which was followed by the addition of compound **36**. A variety of aryl groups were introduced at the 6-position of compound **37** via Suzuki coupling reactions to provide compounds **20–31**.

¹H NMR (400 MHz) spectra were recorded using a Varian Mercury-400 High Performance Digital FT-NMR spectrometer using tetramethylsilane (TMS) as an internal standard. Abbreviations for peak patterns in the NMR spectra are as follows: br=broad, s=singlet, d=doublet, and m=multiplet. Low-resolution mass spectra were obtained with a Finnigan LCQ Deca XP mass spectrometer using a CAPCELL PAK C18 (50 mm×2.0 mm, 5 ZM) or an Agilent ZORBAX Eclipse XDB C18 (50 mm×2.1 mm, 5 ZM) column in positive or negative electrospray mode. The purities of all the compounds were determined by analytical Gilson high-performance liquid chromatography (HPLC) using an YMC ODS3 column (50 mm×4.6 mm, 5 ZM) using the following conditions: $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ eluent at 2.5 mL/min flow [containing 0.1% trifluoroacetic acid (TFA)] at 35 °C, 8 min, gradient 5% CH_3CN to 95% CH_3CN , monitored by UV absorption at 214 nm and 254 nm. TLC analyses were carried out using glass precoated silica gel GF254 plates. The

TLC spots were visualized under UV light. Flash column chromatography was performed using a Teledyne ISCO CombiFlash Rf system. All the solvents and reagents were used as received unless otherwise noted. Anhydrous dimethylformamide was purchased from Acros and was used without further drying. All air- and moisture-sensitive reactions were carried out under an atmosphere of dry argon with heat-dried glassware using standard syringe techniques.

General procedure for the syntheses of 5–19

6-Bromoimidazo[1,2-a]pyridine-3-sulfonic acid (**33**). Chlorosulfonic acid (1.01 mL, 15.3 mmol) was dissolved in chloroform (10 mL), and this solution was added dropwise to 6-bromoimidazo[1,2-a]pyridine (1.00 g, 5.1 mmol) in chloroform (15 mL) over 20 min. The reaction mixture was refluxed for 24 h, allowed to cool to room temperature and concentrated to dryness under vacuum. The crude oily product was treated with diethyl ether (20 mL) and ethanol (10 mL), which resulted in the collection of a white precipitate. The solid was collected by filtration, washed with EtOH and dried to afford 6-bromoimidazo[1,2-a]pyridine-3-sulfonic acid (**33**) (1.38 g, 98% yield). MS *m/z* (ESI) found 275, 277 (M-H)⁺; ¹H NMR (400 MHz, DMSO-*d*⁶) δ 8.93 (dd, *J*=1.8, 0.8 Hz, 1H), 8.30 (s, 1H), 8.13 (dd, *J*=9.5, 1.8 Hz, 1H), 7.95 (dd, *J*=9.5, 0.8 Hz, 1H); the OH on sulfonic acid is missing.

6-(4-fluorophenyl)imidazo[1,2-a]pyridine-3-sulfonic acid (**34**). A solution of **33** (4 g, 14.4 mmol), (4-fluorophenyl)boronic acid (2.4 g, 17.3 mmol), PdCl₂(dppf)-CH₂Cl₂ (590 mg, 0.72 mmol) and K₂CO₃ (7.97 g, 57.8 mmol) in 1,4-dioxane:water (40 mL, 2:1, *v/v*) in a microwave tube was flushed with N₂ for 5 min and then sealed. The tube was placed in the microwave cavity and heated at 90 °C for 1 h. Then, the reaction mixture was evaporated to dryness. The residue was diluted with water (60 mL), filtered and washed with water (20 mL). The pH of the filtrate was adjusted to 1–2 with 1 mol/L aqueous HCl, and white precipitate appeared. The precipitate was filtered and dried under vacuum to give **34** (2.98 g, 70.9% yield). MS *m/z* (ESI) found 291 (M-H)⁺, 293(M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*⁶) δ 8.97 (s, 1H), 8.33 (d, *J*=2.3 Hz, 1H), 8.30 (d, *J*=9.3 Hz, 1H), 8.05 (d, *J*=9.4 Hz, 1H), 8.04 (s, 0H), 7.81–7.67 (m, 2H), 7.44 (t, *J* = 8.3 Hz, 2H); the OH on sulfonic acid is missing.

6-(4-fluorophenyl)imidazo[1,2-a]pyridine-3-sulfonyl chloride (**35**). Compound **34** (2.98 g, 10.2 mmol) was treated with phosphorus oxychloride (60 mL) and refluxed for 24 h. The reaction mixture was cooled to room temperature and treated with DCM (100 mL), poured over ice-cold water (100 mL), and then extracted with DCM (4×50 mL). The organic layers were combined, dried (Na₂SO₄), filtered, and concentrated to dryness under vacuum to give crude **35**. The crude product was purified by flash chromatography to give purified compound **35** (1.6 g, 51%). MS *m/z* (ESI) found 311 (M+H)⁺; ¹H NMR (400 MHz, chloroform-*d*) δ 8.82 (s, 1H), 8.40 (s, 1H), 7.94 (d, *J*=9.3 Hz, 1H), 7.84 (d, *J*=9.3 Hz, 1H), 7.60 (dd, *J*=8.7, 5.2 Hz, 2H), 7.30–7.17 (m, 2H).

3-((1H-imidazol-1-yl)sulfonyl)-6-(4-fluorophenyl)imi-

dazo[1,2-a]pyridine (**5**). NaH (10.3 mg, 0.258 mmol) was first dissolved in 1 mL of anhydrous DMF. Imidazole (10.5 mg, 0.155 mmol) dissolved in 1 mL of anhydrous DMF was slowly added dropwise, and the mixture was stirred for 30 min. Compound **35** (40 mg, 0.129 mmol) dissolved in 1 mL of anhydrous DMF was slowly added dropwise, and the mixture was stirred for 3 h at room temperature. The reaction solution was poured into 0.1 mol/L hydrochloric acid, which was then turned basic using an aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was collected, and distilled under reduced pressure. The residue was purified by flash chromatography to afford compound **5** (26 mg, 60%). MS *m/z* (ESI) found 343 (M+H)⁺; ¹H NMR (400 MHz, chloroform-*d*) δ 8.67 (s, 1H), 8.43 (s, 1H), 8.13 (s, 1H), 7.88 (d, *J*=9.0 Hz, 1H), 7.74 (d, *J*=9.6 Hz, 1H), 7.56–7.39 (m, 2H), 7.36 (s, 1H), 7.27–7.19 (m, 2H), 7.12 (s, 1H). Retention time 3.02 min, 100% pure.

The details of compounds **6–19** are provided in the Supporting Material.

General procedure for the syntheses of 20–31

6-Bromoimidazo[1,2-a]pyridine-3-sulfonyl chloride (**36**). Compound **36** was prepared according to the procedure for **35**. 34% yield; MS *m/z* (EI) found 296(M)⁺; ¹H-NMR (400 MHz, CDCl₃) δ 8.97 (m, 1H), 8.47 (s, 1H), 7.89 (d, *J* = 9.6 Hz, 1H), 7.83 (dd, *J* = 9.6, 1.7 Hz, 1H).

3-((1H-pyrrolo[3,2-c]pyridin-1-yl)sulfonyl)-6-bromoimidazo[1,2-a]pyridine (**37**). NaH (0.88 g, 22 mmol) was suspended in 10 mL of anhydrous DMF and cooled to 0 °C in an ice bath. 1H-pyrrolo[3,2-c]pyridine (1.3 g, 11 mmol) dissolved in 10 mL of anhydrous DMF was slowly added dropwise, and the mixture was stirred for 30 min at 0 °C. Compound **36** (3.9 g, 13.2 mmol) dissolved in 15 mL of anhydrous DMF was added in dropwise, and the reaction mixture was stirred for 4 h at room temperature. The reaction was monitored by TLC. The reaction solution was poured into 0.1 mol/L hydrochloric acid, which was then turned basic using an aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was collected and distilled under reduced pressure. The remaining substance was purified by column chromatography to give purified compound **37** (2.5 g, 60%). MS *m/z* (ESI) found 377 (M+H)⁺; ¹H NMR (400 MHz, chloroform-*d*) δ 8.91 (d, *J*=1.0 Hz, 1H), 8.77 (dd, *J*=1.8, 0.9 Hz, 1H), 8.53 (d, *J*=5.8 Hz, 1H), 8.35 (s, 1H), 7.84 (d, *J*=5.8 Hz, 1H), 7.67 (d, *J*=3.7 Hz, 1H), 7.63 (dd, *J*=9.5, 0.9 Hz, 1H), 7.53 (dd, *J*=9.5, 1.8 Hz, 1H), 6.80 (dd, *J*=3.7, 0.9 Hz, 1H).

3-((1H-pyrrolo[3,2-c]pyridin-1-yl)sulfonyl)-6-phenylimidazo[1,2-a]pyridine (**20**). A solution of **37** (50 mg, 0.133 mmol), phenylboronic acid (24.2 mg, 0.199 mmol), PdCl₂(dppf)-CH₂Cl₂ adduct (5.4 mg, 0.007 mmol) and K₂CO₃ (55 mg, 0.398 mmol) in 1,4-dioxane:water (4 mL, 2:1, *v/v*) in a microwave tube was flushed with N₂ for 5 min then sealed. The tube was placed in a microwave cavity and heated at 90 °C for 60 min. Then, the reaction mixture was evaporated to dryness. The residue was purified by flash chromatography to give **20** (39.7 mg, 80%). MS *m/z* (ESI) found 375 (M+H)⁺;

¹H NMR (400 MHz, chloroform-*d*) δ 8.91 (s, 1H), 8.71–8.69 (m, 1H), 8.53 (d, *J*=5.8 Hz, 1H), 8.43 (s, 1H), 7.91 (d, *J*=6.2 Hz, 1H), 7.79 (dd, *J*=9.4, 0.9 Hz, 1H), 7.75–7.63 (m, 2H), 7.59–7.37 (m, 5H), 6.79 (dd, *J*=3.7, 0.7 Hz, 1H). Retention time 2.82 min, 100% pure.

The details of compounds **21–31** are provided in the Supporting Material.

Molecular docking

The X-ray complex structure of an azaindole compound bound to c-Met (PDB entry: 2WD1^[22]) was downloaded from the PDB database. The Schrödinger software package was used for the modeling studies. First, the structure was subjected to Protein Preparation Wizard to add the hydrogen atoms and refine the structure to eliminate the improper interactions. Then, the Glide program was used to generate the grid file. The receptor grid was defined as an enclosed box centered at the ligand in the ATP binding site. Docking was performed using the Glide software in standard precision (SP) mode with the default parameters^[23]. Finally, the binding interactions were analyzed and illustrated with the Pymol program.

ELISA kinase assay

The effects of the compounds on the activities of various tyrosine kinases were determined using enzyme-linked immunosorbent assays (ELISAs) with purified recombinant proteins. Briefly, 20 μg/mL poly(Glu, Tyr)_{4:1} (Sigma, St Louis, MO, USA) was pre-coated in 96-well plates as a substrate. A 50-μL aliquot of 10 μmol/L ATP solution diluted in kinase reaction buffer (50 mmol/L HEPES [pH 7.4], 50 mmol/L MgCl₂, 0.5 mmol/L MnCl₂, 0.2 mmol/L Na₃VO₄, and 1 mmol/L DTT) was added to each well. Then, 1 μL of various concentrations of compounds diluted in 1% DMSO (*v/v*) (Sigma, St Louis, MO, USA) were then added to each reaction well. DMSO (1%, *v/v*) was used as a negative control. The kinase reaction was initiated adding purified tyrosine kinase proteins diluted in 49 μL of kinase reaction buffer. After incubation for 60 min at 37°C, the plate was washed three times with phosphate-buffered saline (PBS) containing 0.1% Tween 20 (T-PBS). Anti-phosphotyrosine (PY99) antibody (100 μL; 1:500, diluted in 5 mg/mL BSA T-PBS) was then added. After a 30-min incubation at 37°C, the plate was washed three times, and 100 μL of horseradish peroxidase-conjugated goat anti-mouse IgG (1:2000, diluted in 5 mg/mL BSA T-PBS) was added. The plate was then incubated at 37°C for an additional 30 min and washed 3 times. A 100-μL aliquot of a solution containing 0.03% H₂O₂ and 2 mg/mL *o*-phenylenediamine in 0.1 mol/L citrate buffer (pH 5.5) was added. The reaction was terminated by adding 50 μL of 2 mol/L H₂SO₄; as the color changed, the plate was analyzed using a multi-well spectrophotometer (SpectraMAX 190, from Molecular Devices, Palo Alto, CA, USA) at 490 nm. The inhibition rate (%) was calculated using the following equation: $[1 - (A_{490}/A_{490 \text{ control}})] \times 100$. The IC₅₀ values were calculated from the inhibition curves in two separate experiments.

Cell culture

EBC-1, MKN-45, and MKN-1 cells were purchased from Japanese Research Resources Bank (Tokyo, Japan). NCI-H661, A549, KATOIII and DU145 cells were purchased from the American Type Culture Collection (Manassas, VA, USA). NCI-H358, BGC-823, MGC-803 and NCI-H460 were obtained from the Typical Culture Preservation Commission Cell Bank at the Chinese Academy of Sciences. NCI-H3122 was obtained from the National Cancer Institute. MDCK cells were a kind gift from Dr H Eric XU at the Shanghai Institute of Materia Medica. The cells were routinely maintained according to the recommendations of their suppliers^[24].

Cell proliferation assay

Cells were seeded in 96-well tissue culture plates. On the next day, the cells were exposed to various concentrations of compounds and further cultured for 72 h. Cell proliferation was then determined using sulforhodamine B (SRB, from Sigma-Aldrich, St Louis, MO, USA) or a Cell Counting Kit (CCK-8) assay. The IC₅₀ values were calculated by fitting concentration-response curves using a SoftMax pro-based four-parameter method.

Western blot analysis

EBC-1 cells were treated with the indicated dose of compound **31** for 2 h at 37°C and then lysed in 1×SDS sample buffer. The cell lysates were subsequently resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with the appropriate primary antibodies (*ie*, [c-Met (Santa Cruz, CA, USA), phospho-c-Met, phospho-ERK, ERK, phospho-AKT, AKT (all from Cell Signaling Technology, Beverly, MA, USA), and GAPDH (KangChen Biotech, Shanghai, China)) and then with horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG^[25]. The immunoreactive proteins were detected using an enhanced chemiluminescence detection reagent (Thermo Fisher Scientific, Rockford, IL, USA).

Scattering assay

MDCK cells (1.5×10³ cells per well) were plated in 96-well plates and grown overnight. Increasing concentrations of Compound **31** and HGF (50 ng/mL) were added to the appropriate wells, and the plates were incubated at 37°C and 5% CO₂ for 24 h. The cells were fixed with 4% paraformaldehyde for 15 min at room temperature and then stained with 0.2% crystal violet. The assay was performed in triplicate. Images were obtained using an Olympus IX51 microscope.

Results and Discussion

To identify the binding mode of compound **5**, we utilized the Glide program to perform a docking study on **5** in the ATP binding site of c-Met. The crystal structure of 2WD1 was selected as a template, and the protein structure was first refined for glide grid generation. Then, the minimized compound **5** was docked into the binding site. As shown in Figure 2A, the binding conformation of **5** indicated that the hinge

binder was an imidazole group and that the 4-fluoro-benzene group was situated below the side chain of residue Tyr1230 to form a π - π stacking interaction. To verify whether the imidazole unit was the hinge binder, we synthesized 7 compounds by replacing imidazole with different substituted aromatic 5-member rings. As shown in Table 1, when the N atom at the 3-position was removed or changed to the 2-position (6 and 7), the activities dramatically decreased, which informed us that it may be advantageous to have an H-bond receptor at the 3-position to interact with the essential hinge part of the binding site. To test our hypothesis, some H-bond receptors such as a nitril group or an aldehyde group were installed. The results demonstrated that compounds with substitutions at the 3-position exhibited significantly better activities than those with substitutions at the 2-position (comparing 8 to 9 and 10 to 11, respectively). However, compound 12, which had an ethanone structure at the 3-position, did not show good inhibitory activity, indicating that the methyl group caused steric hindrance when the compound approached the carbonyl group of the binding site (comparing compounds 10 and 12).

From Table 1, we found H-bond receptors at the 3-position of the imidazole ring improved activities. Therefore, diversi-

fied bicycle-aromatic rings containing the H-bond acceptor N atom were introduced, and the synthesized compounds were tested in enzymatic assays (Table 2). Compounds 13, 14 and 15 had similar enzyme inhibitory activities against c-Met. When the pyridine ring was replaced by a phenyl ring (16), the compounds lost their activities, reinforcing the finding that pyridine plays an important role in protein-ligand interactions. When a halogen atom was introduced on the carbon adjacent to the N atom (17, 18 and 19), the activities also decreased dramatically, suggesting that the halogen atoms could interfere with nearby residues in the hinge part of the binding site.

The nearly identical activities of 13 and 14 puzzled us regarding their binding conformations because the position of the important nitrogen atoms were different in the pyrrolopyridine rings, which were thought to be essential in H-bond interactions. From the interaction pattern found in the crystal structure 2WD1, compound 13 would bind to the ATP site by forming a hydrogen bond with the backbone of residue Met1160. However, compound 14 had a shifted nitrogen atom, which could not fulfill the requirement of interacting with the hinge part of the protein. Thus, we performed a docking study with the aim of predicting the interaction mode

Table 1. The enzymatic inhibition activities of compounds 5–12.

Cpd.	R ¹	Enzyme inhibition			IC ₅₀ (nmol/L)
		1 μ mol/L	0.1 μ mol/L	0.01 μ mol/L	
5		85.9	13.5	/	181.5 \pm 31.6
6		31.7	27.5	21.1	/
7		5.4	/	/	/
8		97.8	87.7	40.8	/
9		0	9.3	-3.5	/
10		97.7	70	26.2	41.9 \pm 5.1
11		9.4	-25.1	-15.2	/
12		80.7	24.5	6.6	/

The inhibition values are estimated values from two separate experiments. The IC₅₀ values were calculated by the Logit method from the results of at least two independent tests with six concentrations each and expressed as mean \pm SD.




Figure 2. The predicted binding conformation of inhibitors 5 (A) and 14 (B) in the ATP binding site of c-Met based on the docking studies. The ligands were shown in stick model, while the protein were shown in cartoon.

Table 2. The enzymatic inhibition activities of compounds 13–19.

Cpd.	R ¹	Enzyme Inhibition			IC ₅₀ (nmol/L)
		1 μmol/L	0.1 μmol/L	0.01 μmol/L	
13		100	92.1	48.8	15.1±4.5
14		100	96.9	43.3	15.2±4.2
15		97.1	89.1	44	20.2±0.6
16		35.2	29.2	29.4	/
17		44.4	48.4	4.4	/
18		9.8	-17.4	-22.2	/
19		-8.9	-23.4	3	/

The inhibition values are estimated values from two separate experiments. The IC₅₀'s were calculated by the Logit method from the results of at least two independent tests with six concentrations each and expressed as mean±SD.

of compound **14**. As shown in Figure 2B, the binding mode of compound **14** was dramatically different from that of compound **13** because the structure was reversed and a hydrogen bond between the imidazo[1,2-a]pyridine ring and residue

Met1160 was observed. This surprising binding conformation triggered us to pursue further optimizations based on this novel scaffold.

As demonstrated by the prediction of the binding conforma-

tion of compound **14**, the 4-fluoro-benzene group coupled to imidazo[1,2-a]pyridine pointed to the solvent-accessible part of the c-Met. Therefore, different heterocycles or substituted phenyl groups were evaluated for their occupancy of the solvent accessible subpocket (Table 3). Most of the compounds showed excellent c-Met inhibition in an enzymatic assay, but

many of them did not show good cellular activities in EBC-1 cancer cells. The enzyme IC₅₀ values of compounds **24** and **29** were 6.6±1.9 and 224.1±74.8 nmol/L, respectively, while their IC₅₀ values in EBC-1 cells were similar (*ie*, their IC₅₀ values were approximately 500 nmol/L). On the whole, R² with substituted phenyl groups showed better activities than those

Table 3. The enzymatic inhibition activities and cellular activities of compounds 20–31.

Cpd.	R ²	IC ₅₀ (nmol/L)	EBC-1			IC ₅₀ (nmol/L)
			1 μmol/L	0.2 μmol/L	0.04 μmol/L	
20		71.3±18.0	25.4	-8.5	-8.9	/
21		82.3±28.7	88.3	17.8	2.5	326.6±94.1
22		20.7±4.0	89.4	87.6	66.7	80.5±12.3
23		40±1 μmol/L	/	/	/	/
24		224.1±74.8	88.8	8.5	-9.9	543.7±105.6
25		102.0±30.9	90.7	79.0	11.5	447.0±121.3
26		31.4±0.1 μmol/L	/	/	/	/
27		78.2±4.5	27.4	-11.1	-12.6	/
28		74.4±2.1	29.6	-13.5	-10.8	/
29		6.6±1.9	81.7	-3.5	-11.8	539.5±98.3
30		14.8±0.1 μmol/L	/	/	/	/
31		12.8±1.5	91.0	94.8	69.3	19.8±1.6

The inhibition values are estimated values from two separate experiments. The IC₅₀ values were calculated by the Logit method from the results of at least two independent tests with six concentrations each and expressed as mean±SD.

with heterocycles; in particular, compound **31** exhibited strong inhibition on both molecular and cellular levels.

Compound **31** is a potent and selective inhibitor of c-Met

In an enzymatic screen designed to identify c-Met inhibitors, compound **31** was distinguished for its potency against recombinant human c-Met kinase and exhibited an average IC_{50} value of 12.8 nmol/L (Table 3). Accordingly, we were prompted to investigate whether this potency was specifically against c-Met. Thus, the activity of Compound **31** was evaluated against a panel of kinases (Table 4). In contrast to its high potency against c-Met, Compound **31** barely inhibited the kinase activity of other tested tyrosine kinases, including c-Met family member Ron and highly homologous kinases Axl, Tyro3, c-Mer ($IC_{50}>1 \mu\text{mol/L}$), indicating that compound **31** is a selective c-Met inhibitor.

Table 4. Kinase selectivity profile of compound **31**.

Kinase	IC_{50} (nmol/L)
c-Met	12.8±1.5
Ron	>1000
Axl	>1000
Tyro3	>1000
Mer	>1000
ALK	>1000
PDGFR- α	>1000
PDGFR- β	>1000
EGFR	>1000
ErbB2	>1000
ErbB4	>1000
FGFR1	>1000
RET	>1000
KDR	>1000
Flt-1	>1000
c-Src	>1000
EPH-A2	>1000

The ability of Compound **31** to inhibit the enzymatic activities of a panel of recombinant tyrosine kinases was evaluated by ELISA assays, representing IC_{50} s as mean±SD or estimated values.

Compound **31** inhibits c-Met phosphorylation and its downstream signaling pathways

To further assess the cellular activity of Compound **31** against c-Met kinase, we measured its effects on the phosphorylation of c-Met and downstream signaling molecules in EBC-1 cells that harbor an amplified *MET* gene. As shown in Figure 3, Compound **31** significantly inhibited the phosphorylation of c-Met with a complete abolishment at 40 nmol/L in EBC-1 cells, including the phosphorylation of Akt and ERK, which are key downstream molecules of c-Met^[26]. These results suggested that Compound **31** exhibits effective inhibition of c-Met activation and its signaling.




Figure 3. Compound **31** suppresses c-Met phosphorylation and downstream signaling in EBC-1 cells. Cells were treated with indicated concentrations of Compound **31** for 2 h and analyzed by immunoblot.

Compound **31** significantly inhibits c-Met-addicted proliferation

Activated c-Met is known to trigger cancer cell proliferation^[27]. Therefore, we next assessed the effect of Compound **31** on cell proliferation in human cancer cells and genetically engineered cells that harbor different backgrounds of c-Met expression and activation. Compound **31** significantly inhibited the proliferation of the c-Met-constitutively activated EBC-1 and MKN45 cells, with IC_{50} values of 19.8 and 9.9 nmol/L, respectively (Table 5). In contrast, compound **31** showed over 500-fold less potency in cells with low c-Met expression or activation (Table 5). These data indicate that Compound **31** specifically inhibits c-Met-dependent cancer cell growth.

Table 5. Anti-proliferative activity of Compound **31**.

IC_{50} (nmol/L)	Compound 31
EBC-1	19.8±1.6
MKN45	9.9±3.3
A549	>10000
NCI-H3122	>10000
NCI-H358	>10000
NCI-H661	>10000
NCI-H460	>10000
BGC-823	>10000
KATO III	>10000
MGC-803	>10000
MKN-1	>10000
DU145	>10000

The IC_{50} values are shown as the mean±SD (nmol/L) or estimated values from two separate experiments.

Compound **31** inhibits c-Met-dependent cell scattering

Activated HGF/c-Met signaling is also known to promote cell scattering that stimulates cells to abandon their original environment, a hallmark of cancer invasiveness and metastasis^[28]. It has been well documented that MDCK cells, which normally grow in clusters, are disruptive and scatter cell colo-

nies upon HGF stimulation. We thus determined the effect of compound **31** on this cell scattering behavior using MDCK cells stimulated by HGF. As shown in Figure 4, treatment with compound **31** reduced the HGF-induced cell scattering of MDCK cells in a dose-dependent manner, completely blocking the spreading of cells at a dose of 500 nmol/L.




Figure 4. Compound **31** inhibits HGF-induced cell scattering. Cell scattering of MDCK cells induced by HGF were dose-dependently inhibited by Compound **31**. Representative images from two separate experiments are shown (scale bar, 100 µm).

Discussion

Based on the previously identified lead compound **4**, we synthesized an interesting compound **5** during the development of c-Met inhibitors. According to the docking prediction, we proposed that the imidazole of compound **5** would form a hydrogen bonding interaction with the hinge part of the ATP binding site of c-Met. The structure-activity relationships of synthesized compounds **6–12** were consistent with this hypothesis. Further optimization resulted in a novel compound, **14**, which contained a pyrrolo[3,2-c]pyridine scaffold. A docking study of this compound suggested that it could interact with c-Met in a reversed conformation by using the imidazo[1,2-a]pyridine as a hinge binder. Following this finding, further optimization resulted in the synthesis of compound **31**, the most potent compound, which exhibited potent enzymatic inhibition activity with an IC_{50} of 12.8 nmol/L. Compound **31** effectively inhibited overactivated c-Met signaling in EBC-1 cancer cells. In turn, compound **31** suppressed c-Met-dependent cell proliferation and cell scattering. This discovery will benefit other researchers and enable the development of a novel series of c-Met inhibitors as anti-cancer drugs.

An interesting feature of Compound **31** was its selectivity against c-Met. Compound **31** presented IC_{50} values for c-Met in the nanomolar range in a kinase assay and showed more than a 78-fold selectivity over a panel of 16 human kinases, including c-Met family member Ron and highly homologous kinases, such as Axl, Tyro3 and Mer. Consistently, the anti-

proliferative activity of compound **31** was more than 500-fold potent for c-Met-addicted cells in contrast to a panel of tumor cell lines with low c-Met expression and activation levels. In fact, most c-Met inhibitors currently undergoing clinical trials are multi-target inhibitors, which may result in unwanted off-target toxicity^[29]. Specific c-Met inhibitors could largely avoid toxicity arising from the targeting of extra molecules and thus provide a better option for the sub-population of c-Met-driven cancers in the new era of precision medicine. The high specificity and potency of compound **31** give it the potential to act as a tool inhibitor in preclinical use and allows it to be a promising novel drug candidate for further development.

Acknowledgements

We are grateful for financial support from the Foundation of China Postdoctoral Science, the National Natural Science Foundation of China (No 81202391, 91229205, 81473243, 81321092 and 81330076) and the National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" of China (No 2014ZX09507002, 2012ZX09301001-007 and 2013ZX09507001). The SA-SIBS Scholarship Program is also gratefully acknowledged.

Author contribution

Bing XIONG, Jing AI and Dong-mei ZHAO designed the research; Tong-chao LIU, Xia PENG, Yu-chi MA and Yin-chun JI conducted the research; Dan-qi CHEN, Ming-yue ZHENG, Mao-sheng CHENG, Mei-yu GENG and Jing-kang SHEN analyzed the data; Bing XIONG, Jing AI, and Dong-mei ZHAO wrote the paper.

Supplementary information

Chemical experimental procedures and analytical data for the mentioned compounds are available in the supplementary Information at the website of Acta Pharmacologica Sinica.

References

- 1 Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular-cloning of a new transforming gene from a chemically transformed human cell-line. *Nature* 1984; 311: 29–33.
- 2 Holmes O, Pillozzi S, Deakin JA, Carafoli F, Kemp L, Butler PJG, et al. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. *J Mol Biol* 2007; 367: 395–8.
- 3 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science* 2002; 298: 1912–34.
- 4 Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. *Acta Pharmacol Sin* 2010; 31: 1181–8.
- 5 Bottaro DP, Rubin JS, Faletto DL, Chan AML, Kmieciak TE, Vandewoude GF, et al. Identification of the hepatocyte growth-factor receptor as the c-Met protooncogene product. *Science* 1991; 251: 802–4.
- 6 Wang XL, Chen XM, Fang JP, Yang CQ. Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer *in vitro* and *in vivo*. *Acta Pharmacol Sin* 2012; 33: 513–22.

- 7 Ponzetto C, Bardelli A, Zhen Z, Maina F, Dallazonca P, Giordano S, *et al*. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor scatter factor receptor family. *Cell* 1994; 77: 261–71.
- 8 Birchmeier C, Birchmeier W, Gherardi E, Vande WGF. Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 2003; 4: 915–25.
- 9 Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. *Nat Rev Mol Cell Biol* 2010; 11: 834–48.
- 10 Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S, *et al*. c-Met is essential for wound healing in the skin. *J Cell Biol* 2007; 177: 151–62.
- 11 Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. *J Clin Invest* 2002; 109: 857–62.
- 12 He CX, Ai J, Xing WQ, Chen Y, Zhang HT, Huang M, *et al*. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. *Acta Pharmacol Sin* 2014; 35: 89–97.
- 13 Qian J, Zhu CH, Tang S, Shen AJ, Ai J, Li J, *et al*. α 2,6-Hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells. *Acta Pharmacol Sin* 2009; 30: 1039–45.
- 14 Yu Z, Ma YC, Ai J, Chen DQ, Zhao DM, Wang X, *et al*. Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations. *Acta Pharmacol Sin* 2013; 34: 1475–83.
- 15 Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, *et al*. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. *Cancer Res* 1998; 58: 5157–67.
- 16 Umeki K, Shiota G, Kawasaki H. Clinical significance of c-met oncogene alterations in human colorectal cancer. *Oncology* 1999; 56: 314–21.
- 17 Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. *J Med Chem* 2014; 57: 4427–53.
- 18 Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, *et al*. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). *J Med Chem* 2011; 54: 6342–63.
- 19 Atreya CE, Song EK, Messersmith W, Purkey A, Bagby S, Quackenbush K, *et al*. Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models. *Int J Cancer* 2015; 136: 1967–75.
- 20 Munshi N, Jeay S, Li YZ, Chen CR, France DS, Ashwell MA, *et al*. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. *Mol Cancer Ther* 2010; 9: 1544–53.
- 21 Ma YC, Sun GQ, Chen DQ, Peng X, Chen YL, Su Y, *et al*. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors. *J Med Chem* 2015; 58: 2513–29.
- 22 Porter J, Lumb S, Franklin RJ, Gascon-Simorte JM, Calmiano M, Riche KL, *et al*. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. *Bioorg Med Chem Lett* 2009; 19: 2780–4.
- 23 Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, *et al*. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J Med Chem* 2004; 47: 1739–49.
- 24 Patil MA, Lee SA, Macias E, Lam ET, Xu CR, Jones KD, *et al*. Robe of cyclin D1 as a mediator of c-Met- and beta-Catenin-induced hepatocarcinogenesis. *Cancer Res* 2009; 69: 253–61.
- 25 Boccaccio C, Comoglio PM. Opinion-Invasive growth: a MET-driven genetic programme for cancer and stem cells. *Nat Rev Cancer* 2006; 6: 637–45.
- 26 Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, *et al*. Only a subset of Met-activated pathways are required to sustain oncogene addiction. *Sci Signal* 2009; 2(100): ra80. doi: 10.1126/scisignal.2000643. Erratum in: *Sci Signal*. 2009 Dec 22; 2(102):er11.
- 27 Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. *Nat Rev Mol Cell Biol* 2010; 11: 834–8.
- 28 Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. *Nature* 1987; 327: 239–42.
- 29 Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. *Nat Rev Drug Discov* 2008; 7: 504–16.